Merck & Co., Inc. is 13.9x more valuable than Royalty Pharma plc by market capitalization ($294.13 B vs $21.16 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RPRX | MRK |
|---|---|---|
| Market cap | $21.16 B | $294.13 B |
| US-listed rank | #601 | #44 |
| Revenue (latest FY) | $2.38B | $65.01B |
| Net income (latest FY) | $770.95M | $18.25B |
| Net margin | 32.4% | 28.1% |
| P/E (trailing FY) | 27.4 | 16.1 |
| SEC filings | 588 | 996 |
Merck & Co., Inc. is 13.9x more valuable than Royalty Pharma plc by market capitalization ($294.13 B vs $21.16 B).
In their latest fiscal years, Royalty Pharma plc reported $2.38B in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Royalty Pharma plc and Merck & Co., Inc., or browse the full rankings.